Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

(+)-N-3-Benzyl-Nirvanol and (−)-N-3-Benzyl-Phenobarbital: New Potent and Selective in Vitro Inhibitors of CYP2C19

Hisashi Suzuki, M. Byron Kneller, Robert L. Haining, William F. Trager and Allan E. Rettie
Drug Metabolism and Disposition March 2002, 30 (3) 235-239; DOI: https://doi.org/10.1124/dmd.30.3.235
Hisashi Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Byron Kneller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L. Haining
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William F. Trager
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allan E. Rettie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Highly potent and selective CYP2C19 inhibitors are not currently available. In the present study, N-3-benzyl derivatives of nirvanol and phenobarbital were synthesized, their respective (+)- and (−)-enantiomers resolved chromatographically, and inhibitor potencies determined for these compounds toward CYP2C19 and other human liver cytochromes P450 (P450s). (−)-N-3-Benzyl-phenobarbital and (+)-N-3-benzyl-nirvanol were found to be highly potent, competitive inhibitors of recombinant CYP2C19, exhibitingKi values of 79 and 250 nM, respectively, whereas their antipodes were 20- to 60-fold less potent. In human liver preparations, (−)-N-3-benzyl-phenobarbital and (+)-N-3-benzyl-nirvanol inhibited (S)-mephenytoin 4′-hydroxylase activity, a marker for native microsomal CYP2C19, with Ki values ranging from 71 to 94 nM and 210 to 280 nM, respectively. At single substrate concentrations of 0.3 μM [(−)-N-3-benzyl-phenobarbital] and 1 μM [(+)-N-3-benzyl-nirvanol] that were used to examine inhibition of a panel of cDNA-expressed P450 isoforms, neither CYP1A2, 2A6, 2C8, 2C9, 2D6, 2E1, nor 3A4 activities were decreased by greater than 16%. In contrast, CYP2C19 activity was inhibited ∼80% under these conditions. Therefore, (+)-N-3-benzyl-nirvanol and (−)-N-3-benzyl-phenobarbital represent new, highly potent and selective inhibitors of CYP2C19 that are likely to prove generally useful for screening purposes during early phases of drug metabolism studies with new chemical entities.

Footnotes

  • ↵1 Present address: Department of Basic Pharmaceutical Sciences, West Virginia University, Box 9530, Morgantown, WV 26505.

  • This work was supported in part by National Institutes of Health Grant GM 32165. Portions of this research were presented previously at the 10th North American Meeting of the International Society for the Study of Xenobiotics in Indianapolis, IN, October 24–28, 2000.

  • Abbreviations used are::
    P450
    cytochrome P450
    MFL
    3-O-methylfluorescein
    CEC
    3-cyano-7-ethoxycoumarin
    DBF
    dibenzylfluorescein
    MAMC
    7-methoxy-4-(aminomethyl)coumarin
    MFC
    7-methoxy-4-(trifluoromethyl)coumarin
    HPLC
    high-performance liquid chromatography
    TLC
    thin-layer chromatography
    DMSO
    dimethyl sulfoxide
    • Received September 13, 2001.
    • Accepted November 28, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 30 (3)
Drug Metabolism and Disposition
Vol. 30, Issue 3
1 Mar 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
(+)-N-3-Benzyl-Nirvanol and (−)-N-3-Benzyl-Phenobarbital: New Potent and Selective in Vitro Inhibitors of CYP2C19
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

(+)-N-3-Benzyl-Nirvanol and (−)-N-3-Benzyl-Phenobarbital: New Potent and Selective in Vitro Inhibitors of CYP2C19

Hisashi Suzuki, M. Byron Kneller, Robert L. Haining, William F. Trager and Allan E. Rettie
Drug Metabolism and Disposition March 1, 2002, 30 (3) 235-239; DOI: https://doi.org/10.1124/dmd.30.3.235

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

(+)-N-3-Benzyl-Nirvanol and (−)-N-3-Benzyl-Phenobarbital: New Potent and Selective in Vitro Inhibitors of CYP2C19

Hisashi Suzuki, M. Byron Kneller, Robert L. Haining, William F. Trager and Allan E. Rettie
Drug Metabolism and Disposition March 1, 2002, 30 (3) 235-239; DOI: https://doi.org/10.1124/dmd.30.3.235
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Functional Characterization of 29 CYP4F2 Variants
  • Exposure-toxicity relation of apatinib
  • ABC phenomenon potentiates anti-HCC efficacy
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics